Cytogen, Inc. (KOSDAQ:217330)

Market Cap	123.65B +25.4%
Revenue (ttm)	25.09B +305.7%
Net Income	-15.23B
EPS	-660.60
Shares Out	23.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,630
Average Volume	428,612
Open	4,655.00
Previous Close	4,670.00
Day's Range	4,450.00 - 4,655.00
52-Week Range	2,260.00 - 11,200.00
Beta	-0.27
RSI	48.68
Earnings Date	Nov 21, 2025

About Cytogen

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is head...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 217330

Financial Performance

In 2024, Cytogen's revenue was 10.91 billion, an increase of 242.63% compared to the previous year's 3.18 billion. Losses were -17.12 billion, 8.54% more than in 2023.